Company

Mondego Bio

Mondego Bio develops PTPN2 inhibitors for cancer immunotherapy.

About

Mondego Bio develops PTPN2 inhibitors targeting the JAK-STAT pathway to enhance immune responses against tumors. Its ZE00-0388 candidate is in preclinical development and is intended to support immunotherapy regimens. Based in Cantanhede, Portugal, the company raised an undisclosed amount in a September 2025 Series A led by Biovance Capital Partners, with OrbiMed and Torrey Pines Investment participating.

1Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in